Tyrian, Becton Dickinson End POC TB Dx Partnership | GenomeWeb

NEW YORK (GenomeWeb News) — Australian firm Tyrian Diagnostics said today that it has discontinued its collaboration with Becton Dickinson to develop a point-of-care diagnostic for active tuberculosis, as neither firm was able to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

Tyrian and BD entered into a collaboration and licensing deal in July 2007 to develop and commercialize TB diagnostic tests based upon biomarkers discovered by Tyrian.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.